Prostaglandin E2 Alters the Differentiation and Function of Antigen-Specific T Cells By Targeting the Metabolic Gene Regulatory Network Downstream of mTORC1
Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic stem cell transplantation to patients without compatible adult donors. Studies in zebrafish and mouse models have shown that the prostaglandin compound, 16,16 dimethyl prostaglandin E2 (PGE2), increases HSC nu...
Saved in:
Published in | Blood Vol. 128; no. 22; p. 552 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
02.12.2016
|
Online Access | Get full text |
Cover
Loading…
Abstract | Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic stem cell transplantation to patients without compatible adult donors. Studies in zebrafish and mouse models have shown that the prostaglandin compound, 16,16 dimethyl prostaglandin E2 (PGE2), increases HSC number and homing. In a human clinical trial of double UCBT, PGE2 decreased time to engraftment, promoted early T cell chimerism, favored generation of long-lived memory CD8+ cells and reduced the incidence of CMV viremia. To obtain mechanistic insight of how PGE2 affects the differentiation program of antigen-specific T cells, we used a well-established model of T effector (TEFF) vs. T memory (TM) differentiation of TCR-transgenic OTI T cells. OTI cells were stimulated with Ova257-264 plus APC with or without PGE2, followed by incubation with either IL-2 or IL-7, which are critical for the development of CD8+ TEFF and TM, respectively. Antigen-specific stimulation with or without PGE2 followed by IL-2 resulted in differentiation to CD44+CD62L- TEFF cells. In contrast, antigen-specific stimulation followed by IL-7 resulted in generation of CD44+CD62L+ central memory T cells. Under these conditions, PGE2 treatment gave rise to a phenotype of CD44-CD62L+Bcl2+Sca1+ cells, consistent with T stem cell memory. Two key pathways regulated by AMPK and mTOR have a decisive role on TM differentiation. AMPK can promote the generation of TM cells. However, we found that PGE2 inhibited AMPK activation indicating that differentiation of TM by PGE2 is not mediated by AMPK. Because the mTORC1-specific inhibitor rapamycin can promote the generation of TM, we focused our studies on the effects of PGE2 on mTORC1. Two classes of direct downstream targets of mTORC1 have been well characterized. mTOR phosphorylates the ribosomal protein S6 kinases (S6K1/2) and the eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BP1/2), both of which control specific steps in the initiation of cap-dependent translation. mTORC1 activation can stimulate glycolysis as well as lipid biosynthesis. This is achieved through the activation of a transcriptional program affecting metabolic gene targets of hypoxia inducible factor 1a (HIF1a) and sterol regulatory element-binding protein (SREBP1/2). HIF1a is regulated downstream of 4E-BP whereas SREBP is regulated downstream of S6K1. Although the mTORC1 inhibitor rapamycin can promote differentiation of TM and Treg cells, recent studies revealed that mTORC1, via its effects on lipid metabolism has a mandatory role on Treg differentiation. We found that PGE2 treatment during antigen-specific stimulation of OTI cells with Ova257-264 resulted in activation of mTOR as determined by phosphorylation of mTOR, 4E-BP and S6K and phosphorylation of Akt on the mTOR-specific site. Surprisingly, when antigen-specific stimulation was followed by IL-7, PGE2 treatment inhibited expression of the 4E-BP downstream targets Myc, HIF1a, the glycolysis genes Glut1, HK2, LDH-A, and the uptake of glucose. Phosphorylation of S6K was also impaired and lipid biosynthesis was suppressed as determined by decreased expression of fatty acid synthase FASN. In contrast, a metabolic program of lipid utilization was activated, characterized by increase of CPT1a, which promotes fatty acid transport in the mitochondria for b-oxidation, and the lipid oxidase Acox1. Mitochondria biogenesis analyzed by Mitotracker staining and expression of mitochondrial genes MTOC-1, TIMM50 and COX5a were also enhanced. In bioenergetics studies control-treated antigen-specific T cells had a glycolytic phenotype with elevated extracellular acidification rate (ECAR) whereas PGE2-treated cells had elevated oxygen consumption rate (OCR) and increased OCR/ECAR ratio, indicating preferential use of oxidative phosphorylation to generate energy. Thus, mTORC1 might regulate differentiation of antigen-specific T cells to TM by promoting lipid biosynthesis upon engaging distinct downstream targets in response to extracellular cues, thereby providing the required fuel for the bioenergetic demands of TM cells. Our studies reveal an unexpected mechanism by which PGE2 regulates the functional fate of T cells by modifying mTORC1 downstream signals and altering T cell metabolic imprints. These findings have implications for harnessing immune memory in the context of tumor-specific and pathogen-specific immunity.
No relevant conflicts of interest to declare. |
---|---|
AbstractList | Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic stem cell transplantation to patients without compatible adult donors. Studies in zebrafish and mouse models have shown that the prostaglandin compound, 16,16 dimethyl prostaglandin E2 (PGE2), increases HSC number and homing. In a human clinical trial of double UCBT, PGE2 decreased time to engraftment, promoted early T cell chimerism, favored generation of long-lived memory CD8+ cells and reduced the incidence of CMV viremia. To obtain mechanistic insight of how PGE2 affects the differentiation program of antigen-specific T cells, we used a well-established model of T effector (TEFF) vs. T memory (TM) differentiation of TCR-transgenic OTI T cells. OTI cells were stimulated with Ova257-264 plus APC with or without PGE2, followed by incubation with either IL-2 or IL-7, which are critical for the development of CD8+ TEFF and TM, respectively. Antigen-specific stimulation with or without PGE2 followed by IL-2 resulted in differentiation to CD44+CD62L- TEFF cells. In contrast, antigen-specific stimulation followed by IL-7 resulted in generation of CD44+CD62L+ central memory T cells. Under these conditions, PGE2 treatment gave rise to a phenotype of CD44-CD62L+Bcl2+Sca1+ cells, consistent with T stem cell memory. Two key pathways regulated by AMPK and mTOR have a decisive role on TM differentiation. AMPK can promote the generation of TM cells. However, we found that PGE2 inhibited AMPK activation indicating that differentiation of TM by PGE2 is not mediated by AMPK. Because the mTORC1-specific inhibitor rapamycin can promote the generation of TM, we focused our studies on the effects of PGE2 on mTORC1. Two classes of direct downstream targets of mTORC1 have been well characterized. mTOR phosphorylates the ribosomal protein S6 kinases (S6K1/2) and the eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BP1/2), both of which control specific steps in the initiation of cap-dependent translation. mTORC1 activation can stimulate glycolysis as well as lipid biosynthesis. This is achieved through the activation of a transcriptional program affecting metabolic gene targets of hypoxia inducible factor 1a (HIF1a) and sterol regulatory element-binding protein (SREBP1/2). HIF1a is regulated downstream of 4E-BP whereas SREBP is regulated downstream of S6K1. Although the mTORC1 inhibitor rapamycin can promote differentiation of TM and Treg cells, recent studies revealed that mTORC1, via its effects on lipid metabolism has a mandatory role on Treg differentiation. We found that PGE2 treatment during antigen-specific stimulation of OTI cells with Ova257-264 resulted in activation of mTOR as determined by phosphorylation of mTOR, 4E-BP and S6K and phosphorylation of Akt on the mTOR-specific site. Surprisingly, when antigen-specific stimulation was followed by IL-7, PGE2 treatment inhibited expression of the 4E-BP downstream targets Myc, HIF1a, the glycolysis genes Glut1, HK2, LDH-A, and the uptake of glucose. Phosphorylation of S6K was also impaired and lipid biosynthesis was suppressed as determined by decreased expression of fatty acid synthase FASN. In contrast, a metabolic program of lipid utilization was activated, characterized by increase of CPT1a, which promotes fatty acid transport in the mitochondria for b-oxidation, and the lipid oxidase Acox1. Mitochondria biogenesis analyzed by Mitotracker staining and expression of mitochondrial genes MTOC-1, TIMM50 and COX5a were also enhanced. In bioenergetics studies control-treated antigen-specific T cells had a glycolytic phenotype with elevated extracellular acidification rate (ECAR) whereas PGE2-treated cells had elevated oxygen consumption rate (OCR) and increased OCR/ECAR ratio, indicating preferential use of oxidative phosphorylation to generate energy. Thus, mTORC1 might regulate differentiation of antigen-specific T cells to TM by promoting lipid biosynthesis upon engaging distinct downstream targets in response to extracellular cues, thereby providing the required fuel for the bioenergetic demands of TM cells. Our studies reveal an unexpected mechanism by which PGE2 regulates the functional fate of T cells by modifying mTORC1 downstream signals and altering T cell metabolic imprints. These findings have implications for harnessing immune memory in the context of tumor-specific and pathogen-specific immunity.
No relevant conflicts of interest to declare. Abstract Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic stem cell transplantation to patients without compatible adult donors. Studies in zebrafish and mouse models have shown that the prostaglandin compound, 16,16 dimethyl prostaglandin E2 (PGE2), increases HSC number and homing. In a human clinical trial of double UCBT, PGE2 decreased time to engraftment, promoted early T cell chimerism, favored generation of long-lived memory CD8+ cells and reduced the incidence of CMV viremia. To obtain mechanistic insight of how PGE2 affects the differentiation program of antigen-specific T cells, we used a well-established model of T effector (TEFF) vs. T memory (TM) differentiation of TCR-transgenic OTI T cells. OTI cells were stimulated with Ova257-264 plus APC with or without PGE2, followed by incubation with either IL-2 or IL-7, which are critical for the development of CD8+ TEFF and TM, respectively. Antigen-specific stimulation with or without PGE2 followed by IL-2 resulted in differentiation to CD44+CD62L- TEFF cells. In contrast, antigen-specific stimulation followed by IL-7 resulted in generation of CD44+CD62L+ central memory T cells. Under these conditions, PGE2 treatment gave rise to a phenotype of CD44-CD62L+Bcl2+Sca1+ cells, consistent with T stem cell memory. Two key pathways regulated by AMPK and mTOR have a decisive role on TM differentiation. AMPK can promote the generation of TM cells. However, we found that PGE2 inhibited AMPK activation indicating that differentiation of TM by PGE2 is not mediated by AMPK. Because the mTORC1-specific inhibitor rapamycin can promote the generation of TM, we focused our studies on the effects of PGE2 on mTORC1. Two classes of direct downstream targets of mTORC1 have been well characterized. mTOR phosphorylates the ribosomal protein S6 kinases (S6K1/2) and the eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BP1/2), both of which control specific steps in the initiation of cap-dependent translation. mTORC1 activation can stimulate glycolysis as well as lipid biosynthesis. This is achieved through the activation of a transcriptional program affecting metabolic gene targets of hypoxia inducible factor 1a (HIF1a) and sterol regulatory element-binding protein (SREBP1/2). HIF1a is regulated downstream of 4E-BP whereas SREBP is regulated downstream of S6K1. Although the mTORC1 inhibitor rapamycin can promote differentiation of TM and Treg cells, recent studies revealed that mTORC1, via its effects on lipid metabolism has a mandatory role on Treg differentiation. We found that PGE2 treatment during antigen-specific stimulation of OTI cells with Ova257-264 resulted in activation of mTOR as determined by phosphorylation of mTOR, 4E-BP and S6K and phosphorylation of Akt on the mTOR-specific site. Surprisingly, when antigen-specific stimulation was followed by IL-7, PGE2 treatment inhibited expression of the 4E-BP downstream targets Myc, HIF1a, the glycolysis genes Glut1, HK2, LDH-A, and the uptake of glucose. Phosphorylation of S6K was also impaired and lipid biosynthesis was suppressed as determined by decreased expression of fatty acid synthase FASN. In contrast, a metabolic program of lipid utilization was activated, characterized by increase of CPT1a, which promotes fatty acid transport in the mitochondria for b-oxidation, and the lipid oxidase Acox1. Mitochondria biogenesis analyzed by Mitotracker staining and expression of mitochondrial genes MTOC-1, TIMM50 and COX5a were also enhanced. In bioenergetics studies control-treated antigen-specific T cells had a glycolytic phenotype with elevated extracellular acidification rate (ECAR) whereas PGE2-treated cells had elevated oxygen consumption rate (OCR) and increased OCR/ECAR ratio, indicating preferential use of oxidative phosphorylation to generate energy. Thus, mTORC1 might regulate differentiation of antigen-specific T cells to TM by promoting lipid biosynthesis upon engaging distinct downstream targets in response to extracellular cues, thereby providing the required fuel for the bioenergetic demands of TM cells. Our studies reveal an unexpected mechanism by which PGE2 regulates the functional fate of T cells by modifying mTORC1 downstream signals and altering T cell metabolic imprints. These findings have implications for harnessing immune memory in the context of tumor-specific and pathogen-specific immunity. Disclosures No relevant conflicts of interest to declare. |
Author | Weaver, Jessica D Herbel, Christoph Patsoukis, Nikolaos Boussiotis, Vassiliki A. |
Author_xml | – sequence: 1 givenname: Christoph surname: Herbel fullname: Herbel, Christoph organization: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA – sequence: 2 givenname: Nikolaos surname: Patsoukis fullname: Patsoukis, Nikolaos organization: Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA – sequence: 3 givenname: Jessica D surname: Weaver fullname: Weaver, Jessica D organization: Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, MA – sequence: 4 givenname: Vassiliki A. surname: Boussiotis fullname: Boussiotis, Vassiliki A. organization: Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA |
BookMark | eNqFkE1OwzAQhS0EEuXnCEi-QIo9TZpkhUqhgAQUQWFrOfY4GFIb2QbUu3BY0pY9i6fRaN57Gn0HZNd5h4SccDbkvILTpvNeD184VEOAYVFstEMGvIAqYwzYLhkwxsZZXpd8nxzE-MYYz0dQDMjPQ_AxybaTTltHL4FOuoQh0vSK9MIagwFdsjJZ72jvobNPpzaLN3TSX1p02dMHKmusogs6xa6L9HxFFzK0mKxrN013mGTju95yhQ7pI7afnUw-rOg9pm8f3umF_3YxBZTLdfNyMX-c8iOyZ2QX8fhvHpLn2eViep3dzq9uppPbTHEGkHGFIzNicqxqnUOlVM1MZXJZFhIalusSq6ZkuiwKA1qasWxqWWMFelzWEqpmdEiKba_qYcSARnwEu5RhJTgTa8Rig1isEQsA0eNdq8-dbXPYP_dlMYioLDqF2gZUSWhv_2n4BXssiqc |
ContentType | Journal Article |
Copyright | 2016 American Society of Hematology |
Copyright_xml | – notice: 2016 American Society of Hematology |
DBID | 6I. AAFTH AAYXX CITATION |
DOI | 10.1182/blood.V128.22.552.552 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology Anatomy & Physiology |
EISSN | 1528-0020 |
EndPage | 552 |
ExternalDocumentID | 10_1182_blood_V128_22_552_552 S0006497119305531 |
GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6I. 6J9 AAEDW AAFTH AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 0R~ 0SF AALRI AAYXX ADVLN AFETI AITUG AKRWK AMRAJ CITATION H13 |
ID | FETCH-LOGICAL-c1022-1ce3f30a6c9d428cc90f8f4a75a2b04d7e8b70d755f2daf6ab9a9e82d679a28b3 |
IEDL.DBID | ABVKL |
ISSN | 0006-4971 |
IngestDate | Thu Sep 12 19:57:12 EDT 2024 Fri Feb 23 02:36:46 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 22 |
Language | English |
License | This article is made available under the Elsevier license. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1022-1ce3f30a6c9d428cc90f8f4a75a2b04d7e8b70d755f2daf6ab9a9e82d679a28b3 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0006497119305531 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1182_blood_V128_22_552_552 elsevier_sciencedirect_doi_10_1182_blood_V128_22_552_552 |
PublicationCentury | 2000 |
PublicationDate | 2016-12-02 |
PublicationDateYYYYMMDD | 2016-12-02 |
PublicationDate_xml | – month: 12 year: 2016 text: 2016-12-02 day: 02 |
PublicationDecade | 2010 |
PublicationTitle | Blood |
PublicationYear | 2016 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
SSID | ssj0014325 |
Score | 2.25549 |
Snippet | Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic stem cell transplantation to patients without compatible adult... Abstract Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic stem cell transplantation to patients without compatible... |
SourceID | crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | 552 |
Title | Prostaglandin E2 Alters the Differentiation and Function of Antigen-Specific T Cells By Targeting the Metabolic Gene Regulatory Network Downstream of mTORC1 |
URI | https://dx.doi.org/10.1182/blood.V128.22.552.552 |
Volume | 128 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhoY9LSTctTR9hDqU373plybKOXidL0nTTEjYhNyPrAQu73pBsD_tf8mMzkuXSQskhB4MfkjCe8cw30ow-Qr4aX96YO54wx_KEMWqSglORcK0RzfOsEc5XI88u8tMr9v2G3-yQqq-F8WmV0fZ3Nj1Y63hnFL_m6Hax8DW-6E6lGCMESTn3tdR7FNEv_p175eT6_MefxQSW0Y7IAINn3yEW8iCyHoXs8OE1GukhpUPOw_F_F_WX25nukzcRL0LZvdJbsmPbATkoW4yVV1v4BiGDM0yND8iLSX_2qup53Abk5Swunx-Qh1--xkMF2o5FCycUSr9Yfg-IAuE4UqVsOmEBtoEper1wsXZQ4hPUtiQw1ruFhjlUdrm8h8kW5iGfHL1gGGlmN6haS2ziN7WGy47ufn23hYsu6RyO_Zy2z3Ff-ZFX85-X1fgduZqezKvTJNIzJNqHiclY28xlqcq1NBjEaC1TVzimBFe0SZkRtmhEagTnjhrlctVIJW1BTS6kokWTvSe77bq1HwiMpeFCKCuZbJhJtXReh1C9uPT71YtDMuwlUt92u3DUIXopaB1EWHsR1pTWKD5_HJKil1v9jzrV6Cme7vrx-V0_kdeIpwKvUUo_k93N3W_7BTHLpjmKOnmEqP3s_BFeEeq5 |
link.rule.ids | 315,783,787,27581,27936,27937,45675 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBZLlnZ7KW22pdunDqU3J44sWdbR8W5Iu0laFu-yNyHrAYHEWXbTQ_5Lf2xHslxaKD30IPBDEsYzzHwjzehD6KPx5Y25Ywl1NE8oJSYpGOEJ0xrQPMsa7nw18nKVz6_pl1t2e4SqvhbGp1VG29_Z9GCt45Nx_Jvju_Xa1_iCOxV8AhAkZczXUh8DGuBsgI7L6c3l4tdmAs1IR2QAwbMfEAt5AFmPQ3b46AaM9IiQEWOh_d1F_eZ2Zs_Q04gXcdl90nN0ZNshOi1biJW3B_wJhwzOsDQ-RI-m_dVJ1fO4DdHjZdw-P0U_vvkaDxVoO9YtviC49JvlDxhQID6PVCn7TlgY-uAZeL1ws3O4hDegbUlgrHdrjWtc2c3mAU8PuA755OAFw0xLuwfV2kAXf6g1vuro7nf3B7zqks7xuV_T9jnuWz_ztv56VU1eoOvZRV3Nk0jPkGgfJiYTbTOXpSrXwkAQo7VIXeGo4kyRJqWG26LhqeGMOWKUy1UjlLAFMTkXihRN9hIN2l1rXyE8EYZxrqygoqEm1cJ5HQL1YsKfV8_P0KiXiLzrTuGQIXopiAwilF6EkhAJ4vPtDBW93OQf6iTBU_x76Ov_H_oBnczr5UIuPq8u36AngK0Cx1FK3qLB_v67fQf4Zd-8j_r5EwDf7K4 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prostaglandin+E2+Alters+the+Differentiation+and+Function+of+Antigen-Specific+T+Cells+By+Targeting+the+Metabolic+Gene+Regulatory+Network+Downstream+of+mTORC1&rft.jtitle=Blood&rft.au=Herbel%2C+Christoph&rft.au=Patsoukis%2C+Nikolaos&rft.au=Weaver%2C+Jessica+D&rft.au=Boussiotis%2C+Vassiliki+A.&rft.date=2016-12-02&rft.pub=Elsevier+Inc&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=128&rft.issue=22&rft.spage=552&rft.epage=552&rft_id=info:doi/10.1182%2Fblood.V128.22.552.552&rft.externalDocID=S0006497119305531 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |